A Study of Suvecaltamide in Adults With Moderate to Severe Residual Tremor in Parkinson's Disease

Completed · Phase 2 · Has a placebo group

Conditions studied: Parkinson Disease, Tremor

In brief

This is a 17-week double-blind, placebo-controlled, randomized, flexible-dosing, parallel-group, multicenter study designed to evaluate the efficacy and safety of suvecaltamide for the treatment of moderate to severe residual tremor in adult participants with Parkinson's disease (PD). The target population represents participants who have tremor that is not adequately controlled by PD medications and that interferes with their activities of daily living (ADL) and/or with their performance of tasks.

Key facts

Study ID
NCT05642442
Run by
Jazz Pharmaceuticals
People needed
169
Starts
2022-12-01
Expected to finish
2024-11-11
Last updated by the study team
2026-01-15

Who can join

Age: 40 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.